Published in Immunology on November 17, 2007
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect Genet Evol (2011) 0.98
Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters. PLoS Negl Trop Dis (2016) 0.78
Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis. J Immunol (2016) 0.77
Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice. PLoS Negl Trop Dis (2015) 0.76
Molecular expression and enzymatic characterization of thioredoxin from the carcinogenic human liver fluke Opisthorchis viverrini. Parasitol Int (2011) 0.76
Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates. Parasite Immunol (2012) 0.76
Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters. PLoS One (2012) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol (1991) 11.04
The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg (2001) 6.02
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med (1993) 5.71
Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A (1991) 4.95
Bacterial endotoxins and host immune responses. Adv Immunol (1979) 4.50
Origin of murine B cell lineages. Annu Rev Immunol (1993) 3.82
The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med (2001) 3.63
Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol (1992) 3.39
The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol (2001) 3.21
A case for regulatory B cells. J Immunol (2006) 3.20
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
T-Independent immune response: new aspects of B cell biology. Science (2000) 2.63
Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol (1995) 2.51
Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev (1993) 2.37
Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev (2005) 2.33
Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis. Clin Exp Immunol (1984) 2.13
Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun (1993) 2.10
Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol (1991) 2.00
IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol (2001) 1.99
Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway. J Immunol (1984) 1.95
Oligosaccharide-specific induction of interleukin 10 production by B220+ cells from schistosome-infected mice: a mechanism for regulation of CD4+ T-cell subsets. Proc Natl Acad Sci U S A (1994) 1.89
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun (2002) 1.85
A unique cascade of oxidoreductases catalyses trypanothione-mediated peroxide metabolism in Crithidia fasciculata. Biol Chem (1997) 1.69
Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med (2000) 1.63
In susceptible mice, Leishmania major induce very rapid interleukin-4 production by CD4+ T cells which are NK1.1-. Eur J Immunol (1995) 1.50
IL-13 is a susceptibility factor for Leishmania major infection. J Immunol (2000) 1.38
Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun (1995) 1.35
The molecular evolution of Trypanosomatidae. Adv Parasitol (2001) 1.33
Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis (1996) 1.29
The importance of TGF-beta in murine visceral leishmaniasis. J Immunol (1998) 1.24
Leishmania-host-cell interaction: complexities and alternative views. Parasitol Today (2000) 1.23
B-cell-derived IL-10: production and function. Methods (1997) 1.22
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease. J Exp Med (1995) 1.18
Interaction of Leishmania gp63 with cellular receptors for fibronectin. Infect Immun (1999) 1.17
Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol (1995) 1.15
Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. J Immunol (1998) 1.14
B-cell outgrowth and ligand-specific production of IL-10 correlate with Th2 dominance in certain parasitic diseases. Exp Parasitol (1996) 1.12
Novel vaccine strategies to T-independent antigens. J Microbiol Methods (2001) 1.12
Complementary antioxidant defense by cytoplasmic and mitochondrial peroxiredoxins in Leishmania infantum. Free Radic Biol Med (2002) 1.09
An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice. Exp Parasitol (1996) 1.08
Polyclonal B-cell stimulation by L3T4+ T cells in experimental leishmaniasis. Infect Immun (1988) 1.02
Costimulation and the regulation of antimicrobial immunity. Immunol Today (1995) 1.00
Hypergammaglobulinaemia in Leishmania donovani infected hamsters: possible association with a polyclonal activator of B cells and with suppression of T cell function. Clin Exp Immunol (1985) 0.99
Effect of glycolipids of Leishmania parasites on human monocyte activity. Inhibition by lipophosphoglycan. J Immunol (1990) 0.98
Immunity and immunosuppression in experimental visceral leishmaniasis. Braz J Med Biol Res (2004) 0.97
Immune response regulation by leishmania secreted and nonsecreted antigens. J Biomed Biotechnol (2007) 0.95
Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence. Infect Immun (2000) 0.94
Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation. Infect Immun (2001) 0.93
Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment. Immunol Lett (2005) 0.93
Cytokines and Ly-1 (B1) B cells. Int Rev Immunol (1992) 0.92
The Trypanosoma cruzi trans-sialidase is a T cell-independent B cell mitogen and an inducer of non-specific Ig secretion. Int Immunol (2002) 0.92
A 24,000 MW Trypanosoma cruzi antigen is a B-cell activator. Immunology (1998) 0.91
Two linked genes of Leishmania infantum encode tryparedoxins localised to cytosol and mitochondrion. Mol Biochem Parasitol (2004) 0.90
Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice. Infect Immun (2006) 0.88
Isotype commitment in the in vivo immune responses. II. Polyclonal plaque-forming cell responses to lipopolysaccharide in the spleen and bone marrow. Eur J Immunol (1983) 0.87
Identification of antibodies to Leishmania silent information regulatory 2 (SIR2) protein homologue during canine natural infections: pathological implications. Immunol Lett (2003) 0.85
A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. Infect Immun (2000) 0.82
Disease susceptibility and development of the cytokine repertoire in the murine Leishmania major model. Eur Cytokine Netw (1998) 0.79
Complementary antioxidant defense by cytoplasmic and mitochondrial peroxiredoxins in Leishmania infantum. Free Radic Biol Med (2002) 1.09
Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release (2006) 1.04
Proinflammatory environment dictates the IL-17-producing capacity of human invariant NKT cells. J Immunol (2011) 1.04
Impact of continuous axenic cultivation in Leishmania infantum virulence. PLoS Negl Trop Dis (2012) 1.00
Targeted disruption of cytosolic SIR2 deacetylase discloses its essential role in Leishmania survival and proliferation. Gene (2005) 0.96
Immune response regulation by leishmania secreted and nonsecreted antigens. J Biomed Biotechnol (2007) 0.95
Live attenuated Leishmania vaccines: a potential strategic alternative. Arch Immunol Ther Exp (Warsz) (2008) 0.95
Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers. Int J Pharm (2007) 0.94
Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment. Immunol Lett (2005) 0.93
Application of an improved enzyme-linked immunosorbent assay method for serological diagnosis of canine leishmaniasis. J Clin Microbiol (2010) 0.92
Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells. J Immunol (2011) 0.91
Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein-encoding allele elicits attenuated Chagas' disease in mice. Immunol Lett (2003) 0.90
Two linked genes of Leishmania infantum encode tryparedoxins localised to cytosol and mitochondrion. Mol Biochem Parasitol (2004) 0.90
Characterization of the biology and infectivity of Leishmania infantum viscerotropic and dermotropic strains isolated from HIV+ and HIV- patients in the murine model of visceral leishmaniasis. Parasit Vectors (2013) 0.89
Differential roles of PI3-Kinase, MAPKs and NF-kappaB on the manipulation of dendritic cell T(h)1/T(h)2 cytokine/chemokine polarizing profile. Mol Immunol (2009) 0.88
Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int Immunopharmacol (2008) 0.88
Leishmania-infected MHC class IIhigh dendritic cells polarize CD4+ T cells toward a nonprotective T-bet+ IFN-γ+ IL-10+ phenotype. J Immunol (2013) 0.86
Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm (2008) 0.86
Human periprostatic white adipose tissue is rich in stromal progenitor cells and a potential source of prostate tumor stroma. Exp Biol Med (Maywood) (2012) 0.85
TLR2-induced IL-10 production impairs neutrophil recruitment to infected tissues during neonatal bacterial sepsis. J Immunol (2013) 0.84
Exoproteome dynamics in Leishmania infantum. J Proteomics (2013) 0.84
Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci (2007) 0.83
Serological evaluation of experimentally infected dogs by LicTXNPx-ELISA and amastigote-flow cytometry. Vet Parasitol (2008) 0.83
Leishmania cytosolic silent information regulatory protein 2 deacetylase induces murine B-cell differentiation and in vivo production of specific antibodies. Immunology (2006) 0.83
Metabolic variation during development in culture of Leishmania donovani promastigotes. PLoS Negl Trop Dis (2011) 0.83
In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol (2010) 0.83
Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. ChemMedChem (2010) 0.82
The Leishmania infantum cytosolic SIR2-related protein 1 (LiSIR2RP1) is an NAD+ -dependent deacetylase and ADP-ribosyltransferase. Biochem J (2008) 0.82
Evaluation of Leishmania species reactivity in human serologic diagnosis of leishmaniasis. Am J Trop Med Hyg (2009) 0.82
Prevalence of antibodies to Leishmania infantum and Toxoplasma gondii in horses from the north of Portugal. Parasit Vectors (2013) 0.82
P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry A (2011) 0.81
Knockdown of asparagine synthetase A renders Trypanosoma brucei auxotrophic to asparagine. PLoS Negl Trop Dis (2013) 0.81
The contribution of Toll-like receptor 2 to the innate recognition of a Leishmania infantum silent information regulator 2 protein. Immunology (2009) 0.81
Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies. Nanomedicine (Lond) (2012) 0.80
Sensitivity of P-glycoprotein tryptophan residues to benzodiazepines and ATP interaction. Biophys Chem (2006) 0.78
Substituted phenols as pollutants that affect membrane fluidity. J Environ Biol (2008) 0.78
Anti-leishmanial activity of the bisnaphthalimidopropyl derivatives. Parasitol Int (2011) 0.78
Effect of nonsteroidal anti-inflammatory drugs on the cellular membrane fluidity. J Pharm Sci (2008) 0.78
A method for functional mouse MDR3 P-glycoprotein reconstitution in Escherichia coli lipids. Anal Biochem (2005) 0.77
Molecular karyotype analysis of Perkinsus atlanticus (Phylum Perkinsozoa) by pulsed field gel electrophoresis. Eur J Protistol (2007) 0.76
Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype. Eur J Pharmacol (2007) 0.76
Surface functionalization of polymeric nanospheres modulates macrophage activation: relevance in leishmaniasis therapy. Nanomedicine (Lond) (2015) 0.75
AMP-activated Protein Kinase As a Target For Pathogens: Friends Or Foes? Curr Drug Targets (2016) 0.75
Effect of anti-inflammatory drugs on splenocyte membrane fluidity. Anal Biochem (2005) 0.75
In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer. Pharm Res (2010) 0.75
Benzodiazepine-mediated structural changes in the multidrug transporter P-glycoprotein: an intrinsic fluorescence quenching analysis. J Membr Biol (2008) 0.75